Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.26
-1.53 (-0.75%)
AAPL  263.11
-1.24 (-0.47%)
AMD  199.80
-0.32 (-0.16%)
BAC  52.37
-0.99 (-1.86%)
GOOG  301.42
-2.52 (-0.83%)
META  640.82
-2.40 (-0.37%)
MSFT  399.96
+0.36 (0.09%)
NVDA  186.04
-1.94 (-1.03%)
ORCL  158.94
+2.77 (1.77%)
TSLA  405.43
-5.89 (-1.43%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.